A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males.
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2010
At a glance
- Drugs Pivagabine (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Pharmacodynamics; Therapeutic Use
- 13 Jan 2010 Results reported in a CeNeRx Biopharma media release.
- 19 Jan 2009 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History